Importantly, our previous findings provided the first evidence that, unlike lapatinib or tucatinib, the superior activity of pan-HER-targeting neratinib against mouse and human HER2-positive tumour lines in vitro and brain metastases in vivo is associated with neratinib’s unique ability to directly induce cell death by ferroptosis [23]. Here, ERBB2 is linked to neoplasm.